Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: M. Ramle who wrote (272)	7/22/1997 10:15:00 PM
From: John Metcalf	of 10280

With all due respect, the quarterly statement should be a non-event. No one can expect revenues to be up, with no Allegra royalties and no other products on the market. If expenses are up, that might signal an uptick in clinical trials pace. Not likely, as the progress of trials has been reported. With a long wait until the FDA rules on levalbuterol, and a long wait until Allegra royalties begin, sell-on-the-news (of levalbuterol NDA) seems to be the predominant motivator for the recent drifting of share price. Most investors calculate that there will be time enough to buy back in. What could upset their plans? An ICE Claritin deal, for one. For that reason, I would be afraid to be out of SEPR stock. OTOH, I'm taking my time to buy more.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next